[{"id":"3b32d8a5-c5ea-4195-a505-ea0c6246c9c2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04119024","created_at":"2021-01-18T20:07:53.813Z","updated_at":"2025-02-25T12:27:21.879Z","phase":"Phase 1","brief_title":"Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors","source_id_and_acronym":"NCT04119024","lead_sponsor":"Jonsson Comprehensive Cancer Center","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Imunace (teceleukin) • MB-101 • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 11/27/2019","start_date":" 11/27/2019","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2025-02-24"},{"id":"4122017d-37fb-40e3-a993-7bf5c634b108","acronym":"","url":"https://clinicaltrials.gov/study/NCT01443468","created_at":"2021-01-18T05:59:05.738Z","updated_at":"2025-02-25T13:39:04.583Z","phase":"","brief_title":"Clinical and Genetic Studies of Li-Fraumeni Syndrome","source_id_and_acronym":"NCT01443468","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 5000","initiation":"Initiation: 01/17/2012","start_date":" 01/17/2012","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2025-02-21"},{"id":"2e85a5b8-b10e-4206-ac90-9608e25af12e","acronym":"SWOG S1609","url":"https://clinicaltrials.gov/study/NCT02834013","created_at":"2021-01-29T07:12:52.961Z","updated_at":"2025-02-25T16:36:45.708Z","phase":"Phase 2","brief_title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","source_id_and_acronym":"NCT02834013 - SWOG S1609","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":" | ","alterations":" PD-L1 overexpression","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar) • MK-1088"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 818","initiation":"Initiation: 01/30/2017","start_date":" 01/30/2017","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2025-02-06"},{"id":"0d376833-0db0-4c3f-a481-a0fdb012621c","acronym":"","url":"https://clinicaltrials.gov/study/NCT04449549","created_at":"2021-01-18T21:24:29.334Z","updated_at":"2024-07-02T16:34:25.844Z","phase":"Phase 2","brief_title":"Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel","source_id_and_acronym":"NCT04449549","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" NF1","pipe":"","alterations":" ","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • nilotinib"],"overall_status":"Recruiting","enrollment":" Enrollment 34","initiation":"Initiation: 08/24/2020","start_date":" 08/24/2020","primary_txt":" Primary completion: 04/02/2025","primary_completion_date":" 04/02/2025","study_txt":" Completion: 04/08/2025","study_completion_date":" 04/08/2025","last_update_posted":"2024-06-14"},{"id":"2674053c-0b8b-4f15-84e1-05d33278bb8a","acronym":"","url":"https://clinicaltrials.gov/study/NCT06041516","created_at":"2023-09-18T15:13:22.199Z","updated_at":"2024-07-02T16:34:25.938Z","phase":"Phase 1","brief_title":"Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas","source_id_and_acronym":"NCT06041516","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ADCT-701"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 06/19/2024","start_date":" 06/19/2024","primary_txt":" Primary completion: 10/30/2027","primary_completion_date":" 10/30/2027","study_txt":" Completion: 10/30/2029","study_completion_date":" 10/30/2029","last_update_posted":"2024-06-14"},{"id":"45278662-36a8-4fe3-8690-2d8d82a1f451","acronym":"","url":"https://clinicaltrials.gov/study/NCT05841563","created_at":"2023-05-03T15:04:56.483Z","updated_at":"2024-07-02T16:34:26.037Z","phase":"Phase 1","brief_title":"Clinical Trial of PM54 in Advanced Solid Tumors Patients.","source_id_and_acronym":"NCT05841563","lead_sponsor":"PharmaMar","biomarkers":" BRAF • BRCA1 • BRCA2","pipe":" | ","alterations":" HER-2 positive • BRCA2 mutation • BRCA1 mutation • HR positive • BRAF mutation • BRAF wild-type","tags":["BRAF • BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • BRCA2 mutation • BRCA1 mutation • HR positive • BRAF mutation • BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PM54"],"overall_status":"Recruiting","enrollment":" Enrollment 125","initiation":"Initiation: 04/28/2023","start_date":" 04/28/2023","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-06-14"},{"id":"d3eed236-57f0-420e-a93f-39225269b5bc","acronym":"","url":"https://clinicaltrials.gov/study/NCT05076396","created_at":"2021-10-13T16:58:16.690Z","updated_at":"2024-07-02T16:34:26.128Z","phase":"Phase 1","brief_title":"PM14 Administered Intravenously to Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05076396","lead_sponsor":"PharmaMar","biomarkers":" BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ecubectedin (PM14)"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 09/06/2017","start_date":" 09/06/2017","primary_txt":" Primary completion: 08/13/2025","primary_completion_date":" 08/13/2025","study_txt":" Completion: 08/13/2025","study_completion_date":" 08/13/2025","last_update_posted":"2024-06-14"},{"id":"4e73113a-e7c6-4265-b9e7-7ae0a32bcfd0","acronym":"","url":"https://clinicaltrials.gov/study/NCT06006013","created_at":"2023-08-23T16:10:49.453Z","updated_at":"2024-07-02T16:34:36.827Z","phase":"Phase 2","brief_title":"Cabozantinib in Combination With Atezolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer","source_id_and_acronym":"NCT06006013","lead_sponsor":"Emory University","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 21","initiation":"Initiation: 03/05/2024","start_date":" 03/05/2024","primary_txt":" Primary completion: 12/16/2025","primary_completion_date":" 12/16/2025","study_txt":" Completion: 12/16/2025","study_completion_date":" 12/16/2025","last_update_posted":"2024-06-10"},{"id":"1a3cab9e-cdcf-4503-89c5-149536f7d547","acronym":"ADVL1622","url":"https://clinicaltrials.gov/study/NCT02867592","created_at":"2021-01-18T14:04:35.391Z","updated_at":"2024-07-02T16:35:02.779Z","phase":"Phase 2","brief_title":"Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors","source_id_and_acronym":"NCT02867592 - ADVL1622","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MET • RET • AXL","pipe":" | ","alterations":" MET amplification • MET overexpression • RET mutation • MET mutation • RET rearrangement • AXL overexpression","tags":["MET • RET • AXL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification • MET overexpression • RET mutation • MET mutation • RET rearrangement • AXL overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 109","initiation":"Initiation: 05/18/2017","start_date":" 05/18/2017","primary_txt":" Primary completion: 06/30/2021","primary_completion_date":" 06/30/2021","study_txt":" Completion: 09/21/2024","study_completion_date":" 09/21/2024","last_update_posted":"2024-05-17"},{"id":"4c588aff-2135-457b-8666-0c80b24a07af","acronym":"","url":"https://clinicaltrials.gov/study/NCT02673333","created_at":"2021-01-17T17:22:28.300Z","updated_at":"2025-02-25T16:04:17.123Z","phase":"Phase 2","brief_title":"Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma","source_id_and_acronym":"NCT02673333","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 39","initiation":"Initiation: 02/01/2016","start_date":" 02/01/2016","primary_txt":" Primary completion: 01/11/2019","primary_completion_date":" 01/11/2019","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2024-03-26"},{"id":"d1c8d534-b991-4bdd-aee5-250c8074853d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03833700","created_at":"2023-07-12T22:09:04.322Z","updated_at":"2024-07-02T16:35:16.167Z","phase":"Phase 1","brief_title":"A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)","source_id_and_acronym":"NCT03833700","lead_sponsor":"Eisai Co., Ltd.","biomarkers":" RNF43 • APC • AXIN1 • ZNRF3","pipe":" | ","alterations":" APC mutation • CTNNB1 mutation • RNF43 mutation","tags":["RNF43 • APC • AXIN1 • ZNRF3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e APC mutation • CTNNB1 mutation • RNF43 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e E7386"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 03/05/2019","start_date":" 03/05/2019","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2024-03-06"},{"id":"afe413d7-7e85-457e-9af3-9c556a34d9ac","acronym":"","url":"https://clinicaltrials.gov/study/NCT01396408","created_at":"2021-01-18T05:44:09.814Z","updated_at":"2024-07-02T16:35:17.762Z","phase":"Phase 2","brief_title":"A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours","source_id_and_acronym":"NCT01396408","lead_sponsor":"Canadian Cancer Trials Group","biomarkers":" PTEN • STK11 • NF1","pipe":" | ","alterations":" EGFR mutation • PTEN mutation • NF1 mutation • MTOR mutation • AKT1 amplification","tags":["PTEN • STK11 • NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • PTEN mutation • NF1 mutation • MTOR mutation • AKT1 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sunitinib • temsirolimus"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 137","initiation":"Initiation: 02/09/2012","start_date":" 02/09/2012","primary_txt":" Primary completion: 07/06/2015","primary_completion_date":" 07/06/2015","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-02-26"},{"id":"3598491d-a786-43cb-a54f-9beda42a8ea4","acronym":"ultradian","url":"https://clinicaltrials.gov/study/NCT02934399","created_at":"2021-01-18T14:24:32.801Z","updated_at":"2024-07-02T16:35:29.063Z","phase":"","brief_title":"Dynamic Hormone Diagnostics in Endocrine Disease","source_id_and_acronym":"NCT02934399 - ultradian","lead_sponsor":"Haukeland University Hospital","biomarkers":" CYP1A2","pipe":"","alterations":" ","tags":["CYP1A2"],"overall_status":"Completed","enrollment":" Enrollment 528","initiation":"Initiation: 10/01/2016","start_date":" 10/01/2016","primary_txt":" Primary completion: 11/14/2023","primary_completion_date":" 11/14/2023","study_txt":" Completion: 11/14/2023","study_completion_date":" 11/14/2023","last_update_posted":"2023-11-15"},{"id":"aa8467ad-c072-4b95-8f7a-4e50666ebdc6","acronym":"FAPI PET RDRC","url":"https://clinicaltrials.gov/study/NCT04459273","created_at":"2023-10-21T07:12:20.148Z","updated_at":"2024-07-02T16:35:33.555Z","phase":"Phase 1","brief_title":"Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers","source_id_and_acronym":"NCT04459273 - FAPI PET RDRC","lead_sponsor":"Jonsson Comprehensive Cancer Center","biomarkers":" FAP","pipe":" | ","alterations":" FAP expression","tags":["FAP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FAP expression"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/27/2020","start_date":" 08/27/2020","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2023-10-13"},{"id":"11248825-dc32-4f79-9bb1-22e998cc26ac","acronym":"","url":"https://clinicaltrials.gov/study/NCT00700414","created_at":"2021-01-18T02:37:07.481Z","updated_at":"2024-07-02T16:35:39.211Z","phase":"","brief_title":"International Pediatric Adrenocortical Tumor Registry","source_id_and_acronym":"NCT00700414","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 9999","initiation":"Initiation: 10/01/2001","start_date":" 10/01/2001","primary_txt":" Primary completion: 12/01/2040","primary_completion_date":" 12/01/2040","study_txt":" Completion: 12/01/2040","study_completion_date":" 12/01/2040","last_update_posted":"2023-08-23"},{"id":"cc4fb18b-f792-4ae9-84d7-f106ddc4db2d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04897321","created_at":"2021-05-21T11:52:50.695Z","updated_at":"2024-07-02T16:35:40.645Z","phase":"Phase 1","brief_title":"B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)","source_id_and_acronym":"NCT04897321","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" CD276","pipe":" | ","alterations":" CD276 expression","tags":["CD276"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD276 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • mesna • B7-H3 CAR-T • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 07/06/2022","start_date":" 07/06/2022","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 03/01/2027","study_completion_date":" 03/01/2027","last_update_posted":"2023-08-08"},{"id":"8345a2bb-1573-4cd9-b1fb-21b74a250c41","acronym":"SCOOP","url":"https://clinicaltrials.gov/study/NCT04544995","created_at":"2021-01-18T21:44:26.025Z","updated_at":"2024-07-02T16:35:40.847Z","phase":"Phase 1","brief_title":"Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Pediatric Participants With Solid Tumors (SCOOP)","source_id_and_acronym":"NCT04544995 - SCOOP","lead_sponsor":"GlaxoSmithKline","biomarkers":" TMB • BRCA1 • BRCA2 • BRCA","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • BRCA mutation","tags":["TMB • BRCA1 • BRCA2 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zejula (niraparib) • Jemperli (dostarlimab-gxly)"],"overall_status":"Suspended","enrollment":" Enrollment 116","initiation":"Initiation: 10/06/2020","start_date":" 10/06/2020","primary_txt":" Primary completion: 09/28/2028","primary_completion_date":" 09/28/2028","study_txt":" Completion: 04/12/2029","study_completion_date":" 04/12/2029","last_update_posted":"2023-08-07"},{"id":"a7069631-5a6c-4c6d-b80d-c3ff1abc9085","acronym":"","url":"https://clinicaltrials.gov/study/NCT02637531","created_at":"2021-01-18T12:49:44.221Z","updated_at":"2024-07-02T16:36:14.125Z","phase":"Phase 1","brief_title":"A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549","source_id_and_acronym":"NCT02637531","lead_sponsor":"Infinity Pharmaceuticals, Inc.","biomarkers":" HER-2 • ER • ALK • PGR • MSI","pipe":" | ","alterations":" MSI-H/dMMR • ER negative • PGR negative","tags":["HER-2 • ER • ALK • PGR • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • ER negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • eganelisib (IPI-549)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 219","initiation":"Initiation: 12/01/2015","start_date":" 12/01/2015","primary_txt":" Primary completion: 01/01/2022","primary_completion_date":" 01/01/2022","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2022-04-04"},{"id":"0a7234f9-0a21-4819-ace5-9082ae1d4a9d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02859441","created_at":"2021-01-18T14:02:14.116Z","updated_at":"2024-07-02T16:36:21.931Z","phase":"Phase 1/2","brief_title":"A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab","source_id_and_acronym":"NCT02859441","lead_sponsor":"National Eye Institute (NEI)","biomarkers":" VHL","pipe":" | ","alterations":" VHL mutation","tags":["VHL"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VHL mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Fovista (pegpleranib) • Lucentis (ranibizumab)"],"overall_status":"Completed","enrollment":" Enrollment 3","initiation":"Initiation: 01/23/2017","start_date":" 01/23/2017","primary_txt":" Primary completion: 07/09/2019","primary_completion_date":" 07/09/2019","study_txt":" Completion: 07/09/2019","study_completion_date":" 07/09/2019","last_update_posted":"2021-11-01"},{"id":"f5bb9bb3-4a13-427c-a0c0-821104f69000","acronym":"","url":"https://clinicaltrials.gov/study/NCT02747355","created_at":"2021-01-18T13:27:36.540Z","updated_at":"2024-07-02T16:37:03.677Z","phase":"","brief_title":"Expression of Different Proliferation Biomarkers in Adreno-cortical Tumors","source_id_and_acronym":"NCT02747355","lead_sponsor":"Bnai Zion Medical Center","biomarkers":" TP53 • NRP1 • MCM2 • MCM3 • SEMA3A","pipe":" | ","alterations":" TP53 expression","tags":["TP53 • NRP1 • MCM2 • MCM3 • SEMA3A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 expression"],"overall_status":"Unknown status","enrollment":" Enrollment 70","initiation":"Initiation: 08/18/2016","start_date":" 08/18/2016","primary_txt":" Primary completion: 07/01/2018","primary_completion_date":" 07/01/2018","study_txt":" Completion: 12/01/2019","study_completion_date":" 12/01/2019","last_update_posted":"2019-01-18"},{"id":"72bc3ae3-cf54-400e-9667-b421a769f941","acronym":"","url":"https://clinicaltrials.gov/study/NCT03323359","created_at":"2022-06-11T05:59:36.610Z","updated_at":"2024-07-02T16:37:16.526Z","phase":"","brief_title":"Efficacy and Tolerability of Hemopatch After Hepatic Resection","source_id_and_acronym":"NCT03323359","lead_sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","biomarkers":" CRP","pipe":"","alterations":" ","tags":["CRP"],"overall_status":"Unknown status","enrollment":" Enrollment 98","initiation":"Initiation: 03/17/2017","start_date":" 03/17/2017","primary_txt":" Primary completion: 11/17/2018","primary_completion_date":" 11/17/2018","study_txt":" Completion: 03/17/2019","study_completion_date":" 03/17/2019","last_update_posted":"2017-11-08"},{"id":"82fc007f-dcb0-48de-9fe9-d7204079488e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03262129","created_at":"2021-07-27T21:52:27.353Z","updated_at":"2024-07-02T16:37:18.438Z","phase":"","brief_title":"Type 1 Multiple Endocrine Neoplasia Cohort Study","source_id_and_acronym":"NCT03262129","lead_sponsor":"Centre Hospitalier Universitaire Dijon","biomarkers":" MEN1","pipe":"","alterations":" ","tags":["MEN1"],"overall_status":"Unknown status","enrollment":" Enrollment 2000","initiation":"Initiation: 01/01/2012","start_date":" 01/01/2012","primary_txt":" Primary completion: 01/01/2020","primary_completion_date":" 01/01/2020","study_txt":" Completion: 12/01/2020","study_completion_date":" 12/01/2020","last_update_posted":"2017-08-25"}]